Keytruda (pembrolizumab)

pCPA File Number: 21649
Negotiation Status:
Concluded with an LOI
Indication(s):
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Sponsor/Manufacturer:
Merck Canada
CDA-AMC Project Number:
PC0236
pCPA Engagement Letter Issued:
Negotiation Process Concluded: